23 / 38
Single centre experience: PFS and OS of nal-IRI+5-FU/LV,
stratified by line of therapy
mo, months; mOS, median overall survival; mPFS, median
progression-free survival; NR, not reached
Glassman DC, et al. J Clin Oncol 2018;
36 (suppl 4S): 471 (and poster)
100
0
50
Survival probability
Months
0
5
10
20
15
100
0
50
Survival probability
Months
0
5
10
20
15
mPFS (mo)
mOS (mo)
1
st
-line (n = 4)
10.8
NR
2
nd
-line (n = 20)
4.3
8.4
3
rd
-line (n = 21)
2.4
3.9
>3
rd
-line ( n = 11)
2.5
4.5
PFS
OS
Log-rank test for trend
P = 0.0031
P = 0.0002
PFS of nal-IRI+5-FU/LV by line of therapy
OS of nal-IRI+5-FU/LV by line of therapy